GPC3-CAR-T cells
PreclinicalCell therapy
GPC3-CAR-T cells is one of 26 biologic programs targeting Hepatocellular Carcinoma. It is currently in Preclinical.
1
Indications
3
Total Trials
1
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
797 competitors in Hepatocellular Carcinoma
#DrugCompanyPhaseTrials
1Ibrance
PfizerPreclinical
Viread
GileadPreclinical
Sovaldi
GileadPreclinical
Coreg
Akero TherapeuticsPreclinical
Vermox
WWim Janssens
Preclinical
Opdivo
Bristol-Myers SquibbPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Statin
Bristol-Myers SquibbPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Anlotinib
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hepatocellular Carcinoma3 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GPC3-CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Cell therapy[2]
- Highest Phase
- Preclinical[1]
- Company
- PPeking University